Beam Therapeutics Announced Progress Across Ex Vivo and In Vivo Pipeline of Base Editing Therapeutics and Outlines Key Anticipated 2022 Milestones Said First Subject Anticipated to be Enrolled in BEAM-101 Phase 1/2 Clinical Trial for the Treatment of Sickle Cell Disease in H2 2022

Never miss a trade again with the fastest news alerts in the world!

This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday.

Want the fastest, most accurate stock market intelligence? Want EXCLUSIVE stories originated by Benzinga reporters? Join 10,000+ serious traders in the Benzinga Pro community!

  • The most trusted brand in stock market news
  • Fatest intelligence & alerts
  • Active trader chat rooms
  • Option trade alerts
  • Only comprehensive mobile notifications solution
  • Welcoming & white glove support
Posted In: NewsGuidance
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...